Familial Hypercholesterolemia
- VernacularTitle:Гэр бүлийн хиперхолестеролеми
- Author:
Ganchimeg D
1
;
Otgonbayar I
1
;
Batbold B
1
;
Tulgaa L
1
;
Sodnomtsogt L
1
Author Information
1. Institute of Medical Sciences named after Shagdarsuren T
- Publication Type:Review
- Keywords:
atherosclerosis;
corneal arcus;
hypercholesterolemia;
LDLR;
xanthomа
- From:Mongolian Medical Sciences
2018;186(4):60-67
- CountryMongolia
- Language:Mongolian
-
Abstract:
Familial hypercholesterolemia (FH) (OMIM#143890) is the most common metabolic autosomal disorder. The prevalence of the homozygous FH has been reported as 1 in a million in the general population, compared to much more mild form heterozygous FH with prevalence of 1 in 200-500. Mutations in the low-density lipoprotein receptor (LDLR), apolipoprotein B (ApoB), proprotein convertase subtilin/kexin9 (PCSK9), and low-density lipoprotein receptor adapter protein 1 (LDLRAP1) genes have been linked to FH. These mutations result in a disorder in low-density lipoprotein cholesterol (LDL-C) catabolism, and significantly increasing the levels of LDL-C, total cholesterol in serum, leading to specific clinical signs such as tendon xanthoma, corneal arcus, cardiovascular diseases, and early death from coronary heart disease if left unattended. Therefore, there is an ardent need for early diagnosis followed by aggressive therapeutic intervention and lifestyle modification. Currently, FH can be diagnosed either clinically or genetically. There have three main clinical diagnostic criteria for FH: the US MedPed Program, the Simon Broom Register Group in the UK, and the Netherland’s criteria. The occurrence of so many different LDLR mutations and their widespread distribution throughout the gene imposes severe practical limitations on simple genetic screening. Indeed, exon by exon sequencing of LDLR and other genes in each patient is the best screening genetic methods of choice. Although the hypercholesterolemia associated with FH can be controlled with cholesterol-lowering drug therapy (statins and other), patient response can vary
quite widely.
- Full text:2018-186(4)-60-67.pdf
